Pure Biologics S.A. (WSE: PUR)
Poland flag Poland · Delayed Price · Currency is PLN
17.76
-0.44 (-2.41%)
Nov 21, 2024, 11:37 AM CET

Pure Biologics Company Description

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases.

It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules.

The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.

It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies.

Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.

Pure Biologics S.A.
Country Poland
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 51

Contact Details

Address:
ul. Dunska 11
Wroclaw, 54-427
Poland
Phone 48 795 61 18 11
Website purebiologics.com

Stock Details

Ticker Symbol PUR
Exchange Warsaw Stock Exchange
Fiscal Year January - December
Reporting Currency PLN
ISIN Number PLPRBLG00010
SIC Code 2836

Key Executives

Name Position
Dr. Filip Jelen M.B.A., Ph.D. Co-founder and President of the Management Board
Romuald Apollo Harwas Chief Financial Officer and Member of the Management Board
Dr. Pieter Spee Chief Scientific Officer and Member of the Management Board
Przemyslaw Dudek Head of Information Technology
Dr. Ewelina Swiderek Ph.D. Head of Project Management